An observational study in Rheumatoid Arthritis (RA) and Remote Patient Monitoring, sponsored by University of Ulster. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by University of Ulster · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 314 studies in Arthritis, Rheumatoid with a site in United Kingdom — 18 open to participants now, 40 under way, 3 of them phase 3. Arthritis, Rheumatoid · United Kingdom.
Among the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom, this one is the 67th largest by planned enrollment of the 75 observational ones that give a count, is one of 3 that started in 2026, is one of 75 observational ones, reaches primary completion later than 11 of the 39 other live ones, and was the 314th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →18 of the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom are open now. Recruiting first, the newest first:
Quell Therapeutics Limited · Sites in United Kingdom, Germany, Spain
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18–75
AstraZeneca · Sites in United Kingdom, United States, Argentina and 14 more countries
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom, United States, Argentina and 9 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 18–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
314 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 69 · Phase 3 81 · Phase 4 37
First in 1995; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 210 across the 239 interventional studies, 151 across the 75 observational. Of the 257 that completed or were terminated, 137 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
244 of 314 have an industry lead sponsor. The 10 most frequent:
University of Ulster is the lead sponsor of 96 studies on the registry; 15 are open to participants now.
University of Ulster has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
9 of the studies in Arthritis, Rheumatoid with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT06240299NHS Greater Glasgow and ClydeNeurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR) | 2027-01-29 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The BloodTrackR Usability and Concordance Study (BUCS) is evaluating a novel home-based blood collection device and companion mobile application for people with rheumatoid arthritis. Participants will use the BloodTrackR device to collect a finger-prick blood sample at home and complete symptom assessments through the app.
The study will assess how easy the device and app are to use, whether participants can successfully collect high-quality blood samples outside of a healthcare setting, and how closely the results compare with standard venous blood samples collected by a phlebotomist. Findings will help determine the potential of BloodTrackR to support remote monitoring and reduce reliance on NHS phlebotomy services.
Background:
Blood testing is one of the most important tools in healthcare, but the way samples are collected and processed today creates barriers for both patients and the NHS. Most blood tests require a hospital or GP visit for venous blood draw. This can be inconvenient and stressful for patients, particularly those with long-term conditions who need frequent monitoring, and it places additional demand on already stretched NHS staff. In clinical trials, reliance on centralised sample collection and processing slows recruitment and increases costs. Current alternatives, such as dried blood spot (DBS) sampling, have limitations in accuracy due to the "haematocrit effect," which reduces trust in results.
The impact is significant: patients face delays and additional travel, NHS services struggle with capacity, and healthcare costs increase. There is an urgent need for simple, reliable solutions that support blood testing in the community, reduce workforce pressure, and improve patient experience.
BloodTrackR, is a novel blood collection device and companion mobile app developed by the researchers that allows people collect their own blood samples at home. A key focus of BloodTrackR is the measurement of inflammation in rheumatoid arthritis, which is not visible to clinicians outside clinic visits, so that treatment can be adjusted in real time rather than at the next scheduled appointment. This helps identify early signs of disease flares and ensures disease activity is kept under control. Given that chronic inflammatory conditions are frequently associated with multi-morbidity, BloodTrackR could also provide a platform for monitoring co-occurring conditions, such as diabetes or cardiovascular disease, from the same device. This creates opportunities to consolidate patient monitoring, reduce missed opportunities for treatment adjustment, and ensure therapy is as effective as possible across multiple conditions.
This reusable device incorporates a proprietary plasma separation process that produces dried plasma samples, rather than dried blood spots, overcoming limitations of the haematocrit effect. Built-in sample stabilisation, temperature monitoring, and precise time-stamping safeguard sample quality and integrity during transport and storage. The companion mobile app links samples with patient-reported symptoms and medications, creating rich longitudinal datasets that can inform clinical decision-making, support remote monitoring, and trigger earlier intervention.
This research will evaluate BloodTrackR, a novel blood collection device and companion App designed for use at home or in community settings and in addition, to ascertain:
Aim: This study aims to evaluate the reliability, usability, and acceptability of BloodTrackR-a novel at-home blood/collection device and companion mobile app-to determine its capacity to reduce reliance on NHS phlebotomy services and identify measurable outcomes that indicate its potential to alleviate NHS workforce burden.
Objectives:
Study Design:
The current research is a usability mixed method study and will be conducted in 3 phases:
Methodology:
Recruitment:
Participants n=20 will be recruited via Rheumatoid Arthritis support groups and their charity partners via the group leaders for which our centre has extensive experience working with and who have already provided feedback on early device design. In addition, participants who have previously taken part in research studies under the CI and have provided enduring consent will also be sent information on the study.
The researcher employed onto the study will arrange to attend the group(s) to give an informal talk about the research and leave Participant information sheets (PIS) for those interested and to answer any questions. If after reading the PIS and the participant is happy to proceed, they will be asked to contact the researcher via the contact details provided on the PIS to check their eligibility via a screening questionnaire. If eligible, the researcher will then gain informed consent either by post or in person prior to participants being enrolled onto the study.
Phase 1: Usability and acceptability: Those participants who have consented to participate in the study will be advised that they will receive their BloodTrackR device by post in a pack complete with instructions. This will be supplemented by remote training on the correct use of the BloodTrackR device and companion app, delivered via Microsoft Teams, to support participants in collecting their own capillary blood sample at home and simultaneously log their assessment of disease activity via the Clinical Disease Activity Index (CDAI) and the Routine Assessment of Patient Index data 3 (RAPID 3) assessment questionnaires which measure the participants physical function, symptoms, pain, and overall global health all via the app. The logged data is accessible only to the named researcher(s) and is de-identified. Usability and compliance will be assessed via a structured questionnaire which will be posted out along with the device to complete when the participant has completed the procedure. In addition, the data usage logged by the App will be collected. This feedback will provide rich insight into user experience, barriers to adoption and opportunities for refinement.
Phase 2: Concordance Study Patient-collected capillary device samples collected via the BloodTrackR device will be validated against matched venous blood draws which will be collected around the same time as they self-collect their device based capillary sample. The participant will be asked to return the device with the sample contained in the well to the Personalised Medicine Centre;PMC in the addressed, prepaid envelope provided. The 6ml venous serum sample will be collected by a qualified phlebotomist to confirm quality and integrity against the device-based samples. The qualified phlebotomist will attend the participant's home solely for the purpose of collecting the venous blood sample. They are not a member of the research team and will have no role in, or influence over, the participant's self-collection of the capillary blood sample using the study device and accompanying app. The phlebotomist's involvement is limited to venepuncture procedures. C-reactive protein (CRP) concentration will be compared between the two sample types using ELISA assays at PMC from the device sample and gold standard hospital laboratory analysis (Altnagelvin hospital, Western Health and Social Care Trust). This will confirm whether CRP values from home-collected plasma samples via the device are equivalent to standard of care phlebotomy, in terms of sample quality and clinical reliability of CRP levels detected. In addition, participants will be asked post procedure to participate in a one-to-one interview either via Teams, telephone or face to face (either in their own home or in C-TRIC). Interviews will be digitally recorded (following informed consent), transcribed verbatim and analysed following the template analysis style outlined by Miles and Huberman (1994).
Phase 3: Health Economic Analysis We will conduct an initial health economic assessment of BloodTrackR relative to current NHS phlebotomy practice. Metrics will include time saved per patient (reduced travel, waiting, and clinic time), reduction in staff workload compared with current phlebotomy practice, and early cost modelling (device/test vs \~£50 per current phlebotomy episode). These analyses will provide early evidence of workforce and system-level benefits.
The study population will consist of approximately 20 adults aged 18 years and older with a confirmed diagnosis of rheumatoid arthritis living in or around Derry/Londonderry, Northern Ireland. Participants must be able to understand written and spoken English and have access to WiFi and a smartphone or tablet. Participants will be recruited through rheumatology patient organisations, support groups, community networks, and research recruitment platforms to evaluate the usability, acceptability, and concordance of the BloodTrackR home blood collection platform.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adults aged 18 years and older with rheumatoid arthritis who will use the BloodTrackR home blood collection device and companion mobile application. Participants will collect a blood sample at home and undergo paired venous blood sampling for concordance testing. Usability, acceptability, and user experience will be assessed through questionnaires and interviews.
Device: BloodTrackR - Home Blood Collection Platform
A home-based blood collection device and mobile application that enables remote blood sampling, symptom tracking, temperature monitoring, and sample traceability.
Questionnaire to assess usability of the BloodTrackR Home Blood Collection Platform
Usability of the BloodTrackR device and companion mobile application will be assessed using a study-specific usability questionnaire completed after device use. Participants will indicate whether each step of the blood collection procedure was successfully completed, completed with issues, or not completed, and will provide an overall usability rating on a scale of 0 to 10. Higher scores indicate greater usability and user satisfaction.
Time frame: Immediately after completion of BloodTrackR device use (same day)
Post-Procedure Semi-Structured Interview on BloodTrackR User Experience
Participant experience of using the BloodTrackR device and companion mobile application will be explored through a post-procedure semi-structured interview. Interview questions will explore ease of use, acceptability, perceived benefits, barriers to use, and suggestions for improvement. The responses will be summarised descriptively across participants.
Time frame: Following completion of device use (up to 1 month)
Concordance Between BloodTrackR device and Venous CRP Measurements
Comparison of C-reactive protein (CRP) concentrations obtained from blood samples collected using BloodTrackR and paired venous blood samples analysed using standard laboratory methods.
Time frame: 1 week following device use
Successful Home Blood Sample Collection Rate
Proportion of participants able to successfully collect and return a blood sample using the BloodTrackR device without assistance.
Time frame: Up to 1 day following device use
Estimated Patient Time Associated With Blood Collection
A preliminary health economic assessment will compare BloodTrackR with standard NHS phlebotomy pathways. Estimated patient time associated with blood collection, including travel, waiting, and clinic time, comparing BloodTrackR with standard NHS phlebotomy pathways. Findings will be used to inform future economic evaluations of BloodTrackR.
Time frame: At completion of study participation (up to 3 months)
Estimated Healthcare Staff Workload Associated With Blood Collection
A preliminary health economic assessment will compare BloodTrackR with standard NHS phlebotomy pathways. Estimated healthcare staff workload associated with blood collection procedures comparing BloodTrackR with standard NHS phlebotomy pathways. Findings will be used to inform future economic evaluations of BloodTrackR.
Time frame: At completion of study participation (up to 3 months)
Estimated Blood Collection Cost per Participant
A preliminary health economic assessment will compare BloodTrackR with standard NHS phlebotomy pathways. Estimated cost per participant for blood collection using BloodTrackR compared with standard NHS phlebotomy pathways. Findings will be used to inform future economic evaluations of BloodTrackR.
Time frame: At completion of study participation (up to 3 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Sep 2026, 3 months later.
Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 3 months is below that.
Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ulster